

RECEIVED

NOV 19 2002

TECH CENTER 1600/2800

PATE

GENENT.047



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : De Young, et al.
Appl. No. : 09/619,059
Filed : July 18, 2000
For : STABILIZING
FORMULATION FOR NGF
Examiner : M. ALLEN

) Group Art Unit 1631

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first-class mail in
) an envelope addressed to: United States Patent
) and Trademark Office, P.O. Box 2327
) Arlington, VA 22202, on

November 8, 2002

(Date)

James J. Mullen III, Ph.D., Reg. No. 44,957

#12/C
Plunkett
11/20/02
(NE)

AMENDMENT AND RESPONSE AFTER FINAL

BOX AF

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In response to the final Office Action mailed on June 11, 2002, please consider the following amendments and remarks. A two-month extension of time is requested for the filing of this amendment and response.

IN THE CLAIMS:

Please cancel claim 6 without prejudice.

2. (Twice Amended) A pharmaceutical composition comprising a nerve growth factor (NGF) at a concentration ranging from 0.07 to 20 mg/ml and a pharmaceutically acceptable acetate-containing buffer, wherein the buffer contains an acetate ion concentration of between 5 and 30 mM, and wherein the pharmaceutical composition is of therapeutic purity, adapted for administration to humans.

13. (Thrice Amended) The composition according to claim 2, wherein the nerve growth factor has a concentration of at least 0.1 mg/ml.